Filing Flows › Harvard Bioscience (HBIO) › Capital expenditures
Harvard Bioscience (HBIO) capital expenditures by quarter
Harvard Bioscience's capital expenditures were $688K in Q2 2026 (second quarter 2026), +232% from Q3 2025. Over the last 5 quarters it ranged from $89K (Q2 2025) to $688K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $688K | +232% | +673% |
| Q3 2025 | $207K | +133% | — |
| Q2 2025 | $89K | -83% | — |
| Q1 2025 | $513K | +70% | — |
| Q4 2024 | $301K | — | — |
Q2 2026 at a glance
Harvard Bioscience, Q2 2026: revenue $22.7M (+11% year over year), operating margin -4.3%, net loss $2.9M, operating cash flow $325K. The chart follows the revenue to costs, profit and cash.
Questions
What is Harvard Bioscience's capital expenditures?
Harvard Bioscience's capital expenditures were $688K in Q2 2026 (second quarter 2026), +232% from Q3 2025.
How has Harvard Bioscience's capital expenditures changed?
Over the last 5 quarters it ranged from $89K (Q2 2025) to $688K (Q2 2026).